PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch January 14, 2025
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen November 14, 2024
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development October 30, 2024
